Contact us
Board of Directors


Eduard Enrico Holdener, Chairman, NovImmune, Geneva

Dr Holdener has over 20 years of international pharmaceutical senior executive experience and was most recently Chief Medical Officer of F. Hoffman-La Roche's Pharma Division. He was also Global Head of Pharmaceutical Drug Development at Roche where he was instrumental in establishing and expanding Roche's therapeutic areas and in achieving several key international approvals for oncology, rheumatology, and virology drugs such as MabThera. He also led Roche's development operations in Japan for three years and was a member of the Chugai Co. acquisition and integration team during the Roche/Chugai merger in 2001. Dr Holdener holds a medical degree from the University of Zurich and completed a two year clinical and experimental fellowship in oncology at the University of Kansas Medical School, USA.

 
Bernard Mach, Founder and Chairman of SAB, NovImmune, Geneva

Founder of NovImmune, and former professor and director of the Department of Genetics and Microbiology, Faculty of Medicine, University of Geneva, Bernard Mach is the inventor of cDNA cloning and is specialized in the molecular biology of immune response genes. Bernard was co-founder and member of the SAB of Biogen (1978-1992). He was Chairman of the Lombard Odier Immunology Fund Scientific Advisory Board from 1994 to 2002. He is now Chairman of the SAB of Aravis Venture Associates. Former member of the Board of Directors of Serono and former board member of Lonza as well as Scientific Advisor to various institutes and companies. He was a Member of the Swiss Science Council (1974-1984), is a special member of the Swiss Academy of Medical Sciences and is a Member of the French Academy of Sciences.

 
Jack Barbut, CEO, NovImmune, Geneva

Jack Barbut joined NovImmune as CEO since 2001. He is the former President and Chief Executive Officer of Synarc Inc, San Francisco, (1998-2000) with more than 20 years of professional experience in clinical trials management and drug development. Prior to joining Synarc, Jack Barbut was the founder, Vice-Chairman and President of Clinical Services of Chrysalis International, Inc., (1981-1998) a publicly (NASDAQ) traded global full service, Contract Research Organization (CRO), with 450 employees, USD 60M in sales and USD 150 M in market capitalization when it went public. Today it is part of MDS (NYSE), a global drug development service company with USD 1.2 billion in sales and 11,000 employees. A Swiss citizen, Jack Barbut holds a MS in Electrical Engineering and a ScD in Systems Engineering from the EPFL in Lausanne, Switzerland.

 
Hans-Beat Gürtler, Varuma AG, Basel

Hans-Beat Gürtler has a commercial education and spent most of his professional career with Ciba-Geigy and Novartis. He held various positions with growing responsibility in the agricultural and animal health field in Switzerland and abroad. From 1990 to 2002, he was global CEO of Novartis Animal Health. In late 2002, he joined Varuma, a private investor. He serves as a Board Member in various companies.

 
Joe Manko, BZ Bank, Zurich

Dr. Joseph Manko is investment banker with extensive experience in the international securities markets. At BZ Bank, he is responsible for corporate finance and event-driven strategies. Prior to BZ Bank, Dr. Manko had been with Deutsche Bank and Merrill Lynch in London, New York and Hong Kong. Joseph Manko holds a Juris Doctor degree from the University of Pennsylvania.

 
Martin Velasco, Chairman of the Boad of AC Immune, Geneva

Martin Velasco is an entrepreneur with extensive experience in the electronic, medical and biotech areas. In the June 2000 Business Week special report "The Stars of Europe", he was selected as one of the leaders at the forefront of change in Europe. Mr. Velasco was also dubbed the leading "Business Angel" by the Wall Street Journal European edition in June 1999. On March 2004, Mr. Velasco was elected "Business Angel of the year 2004" by the ASBAN and Bilanz. He serves on the board/advisory board of several high-tech start-ups - including Speedlingua SA in which he serves as Chairman and CEO, Sumerian Networks of which he is Co-Founder and Board Member and AC-Immune in which he serves as Chairman, and Mediabolic in which he serves as Board member. Mr. Velasco is the Founder and Chairman of Infantia Foundation, a philanthropic organization aiding children in the developing world. He is member of the Executive Committee of the Positive Investment Initiative Association and Member of the Board and, a leading microfinance investment advisory company.

 
© NovImmune 2008
π